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Background: Retinol-binding protein 4 (RBP4), a novel adipokine secreted by adipocytes and the liver, has elevated
levels in type 2 diabetes mellitus (T2DM). However, its association with human metabolic diseases remains
controversial. The present study was designed to investigate the associations of plasma RBP4 levels with oxidative
stress, inflammatory markers, and metabolic syndrome (MetS) in a Chinese population.
Method: We evaluated plasma RBP4 levels in a cross-sectional sample of 1748 Chinese men and women aged 50
to 70 years in Guangzhou using an in-house developed and validated sandwich ELISA. Plasma glucose, insulin, lipid
profile, serum adiponectin, adipocyte fatty acid-binding protein (A-FABP), 8-iso-prostaglandin F2α (8-iso PGF2α),
13-(S)-hydroxyoctadecadienoic acid (13-HODE), high-sensitivity C-reactive protein (hsCRP), interleukin 6 (IL6), monocyte
chemotactic protein 1 (MCP1) and tumor necrosis factor α (TNFα) were all measured. MetS was defined according to
the updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian Americans.
Results: Circulating RBP4 levels were positively correlated with A-FABP (r = 0.104, P < 0.001), 8-iso PGF2α (0.236,
P < 0.001), and 13-HODE (0.204, P < 0.001) and were inversely correlated with HDL cholesterol (r = −0.072, P = 0.004).
After multivariable adjustment, the RBP4 levels were strongly associated with MetS and its components. The ORs
(95% CIs) for the comparisons of the extreme quartiles of RBP4 were 3.46 (2.87, 4.42) for MetS, 5.92 (4.47, 8.02) for
hypertriglyceridemia, 1.42 (1.11, 1.68) for reduced HDL cholesterol, 1.87 (1.48, 2.36) for central obesity and 2.74
(2.15, 3.36) for hyperglycemia (all P < 0.001). When we further controlled for adipokines, markers of oxidative stress and
proinflammatory response, the association of RBP4 with central obesity was abolished but not the association with
other MetS components.
Conclusions: Plasma RBP4 levels are associated with an adverse profile of oxidative stress and inflammatory markers
and an increased risk of MetS in this Chinese population. These associations are independent of conventional risk factors.
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Metabolic syndrome (MetS) is a clustering of multiple
metabolic abnormalities, including central obesity, dys-
lipidemia, elevated blood pressure, hyperglycemia and
insulin resistance. MetS plays an important role in the
origin of cardiometabolic diseases, including cardiovas-
cular disease (CVD) and type 2 diabetes mellitus [1-3].
Multiple mechanisms may contribute to MetS develop-
ment, including an abnormal production of adipocyte- se-
creted proteins (adipocytokines), aberrant oxidative stress
and dysregulated proinflammatory responses in tissues
such as the muscle and liver [4-7]. Therefore, it is of vital
importance to identify key risk factors for the early diag-
nosis and intervention of metabolic diseases.
Retinol-binding protein 4 (RBP4), mainly secreted by
adipocytes and the liver, was originally known as the spe-
cific carrier of retinol in circulation [8]. Recent studies
demonstrated that RBP4 levels were increased in obese
and insulin-resistant humans and mouse models; addition-
ally, a genetic or pharmacologic elevation of serum RBP4
causes insulin resistance in normal mice [9-11]. Although
many studies show strong correlations of serum RBP4
levels with the severity of insulin resistance and obesity
and with certain components of MetS, including hyperten-
sion [12], dyslipidemia [12,13], waist/hip ratio [13], cardio-
vascular disease [14,15], and intra-abdominal fat mass
[16], others do not demonstrate these correlations [17-19].
These inconsistencies may result from differences in age,
ethnicity, population size, and the methodological tech-
niques used [20]. Hence, it has yet to be established
whether RBP4 may serve as a risk marker for insulin re-
sistance and type 2 diabetes and to what extent it is associ-
ated with MetS.
Therefore, we examined the association between RBP4
and MetS risk among a middle-aged and elderly Chinese
population. We focused on the correlation of RBP4 with
oxidative stress and inflammatory factors, both of which




The study population consisted of individuals who under-
went the Nutrition and Health of Aging Populations in
South China study, which investigated the associations of
dietary and genetic factors, as well as their interactions,
with aging-related chronic diseases. From March 2008 to
March 2009, 2289 participants aged 50–70 years were re-
cruited from Guangzhou if they had been residents in their
respective cities for 10 years. For this study, participants
were excluded if one or more of the following criteria were
met: younger than 50 years old; had a history of cancer,
diabetes, CVD, or stroke; or had missing data on one com-
ponent of the MetS diagnostic. The study protocol wasapproved by the Institutional Review Board of the Sun
Yat-sen University, and written informed consent was ob-
tained from all participants.
Data collection
Baseline data were collected by trained interviewers via
semi-structured questionnaires during face-to-face inter-
views. The questionnaire was designed based on the pilot
surveys among this population. Information on socio-
demographic factors, health status, and lifestyle practices
(including dietary factors and physical activity) was in-
cluded in the questionnaire. Standing height, body weight,
and waist circumference were measured with the partici-
pants in light indoor clothing and without shoes. Body
mass index was calculated as weight in kilograms divided
by height in meters squared. Two researchers independ-
ently entered the baseline data from the questionnaires,
and the data were further checked by a third researcher
when differences were found. All of the subjects were ex-
amined in the morning after an overnight fast.
Laboratory measurements
Overnight fasting blood samples were collected in tubes
containing liquid EDTA, centrifuged at 4°C, and stored
at −80°C until analysis. Total blood cholesterol, high-
density lipoprotein (HDL) cholesterol, triglycerides and
glucose were measured enzymatically on a Hitachi 7180
Biochemistry Automatic Analyzer (Hitachi, Japan) using
a commercial assay kit (Wako Pure Chemical Industries,
Osaka, Japan). Low-density lipoprotein (LDL) cholesterol
was subsequently calculated using the Friedewald formula
[21]. Plasma insulin concentrations were measured by a
radioimmunoassay (Roche, Indianapolis, IN) that has less
than 0.2% cross-reactivity with proinsulin. A homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated as fasting insulin (in lIU/mL) × fasting glucose
(in mmol/L)/22.5. Serum A-FABP concentrations were
measured using an enzyme-linked immunosorbent assay
(Cayman, Ann Arbor, MI), and the intra- and interassay
CVs were 3.3–7.1% and 2.1–5.7%, respectively.
The serum RBP4 concentrations were measured using
an enzyme-linked immunosorbent assay (AdipoGen, Seoul,
Korea), and the intra- and interassay CVs were 1.92–3.68%
and 6.57–8.59%, respectively. Serum adiponectin concen-
trations were measured using an enzyme-linked immuno-
sorbent assay (AdipoGen, Seoul, Korea), and the intra- and
interassay CVs were 4.1–5.9% and 3.7–6.3%, respectively.
Plasma RBP4 levels were measured in duplicate in plasma
aliquots that had undergone 1 or 2 freeze-thaw cycles
using a competitive enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions with
purified human RBP4 standards (Adipogen, Inc.). The
ELISA samples were run in duplicate. The coefficient of
variation for interassay replicate samples was less than 7%.
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Western blot analysis. The intraassay coefficient of
variation was 1.8–7.6%, and that of the interassay was
3.7–8.8%. Plasma 8-iso PGF2α levels were quantita-
tively determined using an ELISA kit purchased from
Enzo Life Sciences International (Plymouth Meeting,
PA, USA). The assay sensitivity was 16.3 pg/ml (range
6.1–100,000 pg/ml). The intraassay coefficient of vari-
ation was 4.4–11%, and that of the interassay was 5.0–
11%. Plasma 13-HODE concentrations were measured
using a colorimetric competitive enzyme immunoassay
kit (Enzo Life Sciences International). The assay sensi-
tivity was 1.6 pmol/ml (range 0.7–100 pmol/ml). The
intraassay coefficient of variation was 6.4–7.3%, and
that of the interassay was 5.4–11.3%.
Plasma CRP was measured using a particle-enhanced
immunoturbidimetric assay (Ultrasensitive CRP kit, CRM
diagnostic systems, Spain) with microparticles coated with
anti-human CRP antibodies. The precision of the method
in the cut-off value of decision (1.8–2 μg/ml) is less than
5.5%. The serum levels of interleukin 6 (IL6), monocyte
chemotactic protein 1 (MCP1), and tumor necrosis factor
alpha (TNFα) were measured using a MILLIPLEX™ Human
Cytokine/Chemokine panel (Millipore, Billerica, MA). The
intra- and interassay coefficients of variation were 8.1 and
11.6% for IL6, 6.1 and 12.0% for MCP1, and 10.5 and 15.9%
for TNFα, respectively.
Definition of MetS
MetS was defined using the updated National Cholesterol
Education Program/Adult Treatment Panel III criteria for
Asian Americans as having ≥3 of the following compo-
nents: waist circumference ≥90 cm for men or ≥80 cm for
women; triglycerides (TG) ≥1.7 mmol/L; high-density
lipoprotein (HDL) cholesterol <1.03 mmol/L for men
or <1.30 mmol/L for women; blood pressure ≥130/
85 mmHg or current use of antihypertensive medica-
tions; or fasting glucose ≥5.6 mmol/L [22].
Statistical analysis
The normally distributed data were expressed as the
means ± SD, whereas variables with a skewed distribu-
tion were reported as the median (interquartile range)
and log transformed to approximate normality before
analysis. The categorical variables were represented by
frequency and percentage. An analysis of covariance for
the continuous variables and a multivariate logistic re-
gression analysis for the categorical variables were ap-
plied for the comparison according to the RBP4 quartiles.
An analysis of covariance was used to compare the RBP4
levels between genders and geographic locations. Correl-
ation coefficients between RBP4 and metabolic features
were calculated by a partial correlation analysis on ranks
(Spearman correlation). The plasma RBP4 levels weredepicted according to the number of MetS components
using a linear regression model. Multivariate logistic re-
gression models were used to estimate the odds ratios
(ORs) for MetS and its components. Potential confounding
variables, including age, gender, smoking, alcohol drinking,
physical activity, educational level, self-reported CVD, fam-
ily history of diabetes and CVD, CRP, adiponectin, homeo-
static model assessment of insulin resistance (HOMA-IR),
and body mass index (BMI), were controlled for in the re-
gression models. The data management and statistical ana-
lyses were performed with SPSS 16.0 for Windows (SPSS
Inc., Chicago, USA). A P < 0.05 was considered statistically
significant.
Results
A total of 1748 individuals (men and women) were in-
cluded in this study. The characteristics of the study
population according to the quartiles of plasma RBP4
concentrations are summarized in Table 1. Because no
significant differences by sex were observed, men and
women were analyzed together. There were significant
associations between plasma RBP4 concentrations and
BMI and waist circumference: the participants in the high-
est quartile of RBP4 had a higher BMI and waist circum-
ference than those in the lower quartiles of RBP4, after
adjustment for age and sex (P < 0.001). However, no sig-
nificant associations were observed between RBP4 and
current drinking or smoking status.
There were significant correlations between plasma
RBP4 and plasma fasting glucose (P = 0.018) and HOMA-
IR (P = 0.048), but no significant associations with insulin
were found (P = 0.054, Table 2). The participants in the
highest quartile of plasma RBP4 levels had higher plasma
fasting glucose concentrations than those in the lower
quartiles. The plasma RBP4 levels showed a strong and
positive correlation with triglycerides (r = 0.272, P < 0.001).
A higher plasma RBP4 was significantly correlated with
both higher LDL cholesterol (P < 0.001) and lower HDL
cholesterol (P = 0.004). No significant associations were ob-
served for blood pressure. RBP4 was also significantly asso-
ciated with elevated A-FABP levels (r = 0.104, P = 0.001),
but no correlation was observed between RBP4 and adipo-
nectin (r = 0.030, P = 0.151). In addition, RBP4 was strongly
correlated with not only oxidative markers, such as 8-iso
PGF2α (r = 0.236, P < 0.001) and 13-HODE (r = 0.204,
P < 0.001), but also with elevated proinflammatory
molecules, including hsCRP (r = 0.118, P = 0.011), IL6
(r = 0.236, P < 0.001), MCP1 (r = 0.145, P = 0.005) and
TNFα (r = 0.187, P < 0.001).
The RBP4 levels increased gradually with the number
of MetS components (Figure 1). The RBP4 levels in-
creased from 22.52 μg/ml in the participants with none
of the MetS components up to 42.47 μg/ml in those
with all 5 components. The OR (95% CI) for MetS was
Table 1 Characteristics of the study participants according to RBP4 quartiles
Quartile of RBP4
1 (n = 437) 2 (n = 437) 3 (n = 437) 4 (n = 437)
RBP4 (μg/ml) 20.94 ± 4.391 27.97 ± 2.64 33.71 ± 3.05 46.18 ± 8.11
Age (years) 63.89 ± 5.80 65.08 ± 4.81 65.77 ± 4.87 66.23 ± 4.77
Male [n (%)] 236 (54.0) 225 (51.5) 230 (52.6) 219 (50.1)
BMI (kg/m2) 23.49 ± 2.69 24.26 ± 2.86 24.42 ± 3.37 24.71 ± 3.16
Current smoker [n (%)] 109 (24.9) 117 (26.8) 115 (26.3) 122 (27.9)
Current drinker [n (%)] 104 (23.8) 98 (22.4) 94 (21.5) 101 (23.1)
Family history of chronic diseases [n (%)]2 127 (29.1) 117 (26.8) 129 (29.5) 121 (27.7)
Waist circumference (cm) 79.86 ± 10.65 81.48 ± 12.13 84.03 ± 11.75 85.73 ± 12.38
Waist-to-hip ratio 0.84 ± 0.09 0.87 ± 0.07 0.90 ± 0.08 0.92 ± 0.07
Systolic blood pressure (mmHg) 116.81 ± 12.01 115.26 ± 11.96 116.44 ± 11.54 116.56 ± 12.41
Diastolic blood pressure (mmHg) 73.25 ± 8.23 73.88 ± 7.47 74.15 ± 8.42 74.36 ± 8.68
Fasting glucose (mmol/l) 5.62 ± 1.44 5.81 ± 1.93 5.76 ± 1.34 6.02 ± 2.03
Insulin (μU/ml) 13.17 (9.76–16.85)3 13.32 (9.53–17.74) 13.85 (10.08–18.21) 14.36 (10.46–19.82)
HOMA-IR 3.29 (2.44–4.21) 3.44 (2.46–4.58) 3.55 (2.58–4.66) 3.84 (2.80–5.31)
Adiponectin (μg/ml) 15.18 (10.87–23.86) 13.54 (9.25–22.35) 13.79 (8.42–20.89) 13.68 (7.83–19.14)
A-FABP (μg/l) 15.38 (8.45–21.91) 15.61 (8.84–21.38) 15.85 (8.66–23.04) 16.12 (9.62–23.42)
Total cholesterol (mM) 4.67 ± 0.78 4.78 ± 0.72 4.89 ± 0.71 5.00 ± 0.58
Triglyceride (mM) 1.04 ± 0.39 1.13 ± 0.36 1.25 ± 0.42 1.35 ± 0.45
LDL cholesterol (mM) 3.06 ± 0.65 3.18 ± 0.61 3.34 ± 0.62 3.50 ± 0.56
HDL cholesterol (mM) 1.48 ± 0.33 1.42 ± 0.34 1.37 ± 0.29 1.33 ± 0.44
8-iso PGF2-α, pmol/ml 7.42 ± 2.56 7.63 ± 2.49 8.54 ± 2.77 9.32 ± 2.89
13-HODE, pmol/ml 20.2 ± 5.8 21.5 ± 7.7 22.8 ± 6.3 25.1 ± 8.4
hsCRP, μg/ml 0.77 (0.36–1.38) 0.75 (0.39–1.54) 0.82 (0.43–1.74) 0.91 (0.48–1.93)
IL-6, pg/ml 3.05 ± 1.53 3.41 ± 1.75 4.08 ± 1.66 4.43 ± 1.97
MCP-1, pg/ml 227.3 ± 74.5 269.1 ± 92.8 294.8 ± 82.3 334.7 ± 112.6
TNF-α, ng/ml 2.34 ± 0.68 2.55 ± 0.76 2.87 ± 0.82 3.19 ± 1.03
1Mean ± SD (all such values).
2Includes coronary heart disease, stroke, hypertension, and diabetes in a parent or a first-degree sibling.
3Median (interquartile range).
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pared with the lowest quartile, after controlling for age,
sex, BMI, family history of chronic diseases and self-
reported chronic diseases (Table 3). RBP4 was also posi-
tively associated with some of the MetS components,
including hypertriglyceridemia, reduced HDL choles-
terol, elevated LDL cholesterol and hyperglycemia. These
associations were not materially attenuated by further ad-
justment of adipokines and oxidative and inflammatory
markers.
Discussion
In the present study, we observed strong positive asso-
ciations between plasma RBP4 concentrations and the
increased risk of MetS and its components among
middle-aged and elderly Chinese people. Furthermore, achronic inflammatory response was significantly associated
with higher plasma RBP4 levels, and the participants with
those conditions were more likely to have higher RBP4
levels. Additionally, higher RBP4 levels were associated
with oxidative stress, as reflected by a higher concentration
of the oxidative markers.
RBP4, which is mainly secreted from adipocytes and
hepatocytes, has been suggested to be a central regulator
of insulin sensitivity. In animal models, the overexpres-
sion of human RBP4 or the injection of recombinant
RBP4 induces insulin resistance in mice, whereas RBP4
knockout mice showed enhanced insulin sensitivity [23].
Our results suggest that high plasma RBP4 levels were
associated with higher fasting glucose levels, Hb Alc and
HOMA index, which was consistent with the animal
studies. Furthermore, we also observed a positive
Table 2 Multivariable-adjusted Spearman correlation
coefficients of RBP4 and metabolic risk factors1
Spearman correlation coefficient P
BMI 0.108 0.004
Systolic blood pressure 0.034 0.235
Diastolic blood pressure 0.042 0.189





Total cholesterol 0.139 <0.001
Triglycerides 0.272 <0.001
HDL cholesterol −0.072 0.004
LDL cholesterol 0.144 <0.001






1Spearman correlation coefficients were adjusted by age, sex and BMI. A-FABP,
adipocyte fatty acid-binding protein; 13-HODE, 8-iso PGF2α, 8-iso-prostaglandin
F2α; 13-(S)-hydroxyoctadecadienoic acid (13-HODE); hsCRP, high sensitivity
C-reactive protein; RBP-4, retinol-binding protein 4.
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LDL cholesterol and triglycerides, but we observed an
inverse correlation with HDL cholesterol concentrations
in this population. We postulate that the effect of RBP4
on blood lipid concentrations, especially triglycerides,
may be mediated through its effect on the metabolism ofFigure 1 Plasma RBP4 concentrations according to the number
of metabolic syndrome components. P values were calculated
from the multivariable-adjusted general linear regression model. The
covariates adjusted included age, sex, drinking, smoking, family
history of diabetes and cardiovascular diseases.hepatic fatty acids, which regulates the expression of
genes involved in lipid metabolism [24].
In humans, several studies have also shown positive
associations between RBP4 and insulin resistance as well
as features of MetS [25,26]. However, several subsequent
studies have failed to confirm these associations [27,28].
In the current study, we found positive associations of
RBP4 with traditional metabolic traits and an increased
risk of MetS presence. High levels of A-FABP and CRP
and low levels of adiponectin are the well-documented
risk factors for MetS and its components [29-31]. How-
ever, the relationship between RBP4 and A-FABP, CRP
or adiponectin has not been well addressed because of
the controversial reports. Balagopal et al. [32] reported
that RBP4 was positively associated with CRP and nega-
tively associated with adiponectin in a small group of
obese children; however, no correlation between RBP4
and CRP or adiponectin was observed in another study
of 101 hospitalized T2DM patients [33]. With a larger
sample size, Qi Q [25] demonstrated a weak inverse cor-
relation between RBP4 and adiponectin levels, but no
correlation was detected between RBP4 and CRP levels.
In this study, we indeed found a moderate inverse correl-
ation between RBP4 and CRP levels, but no correlation
was observed between RBP4 and adiponectin. Interest-
ingly, we observed a positive association between RBP4
and A-FABP. RBP4 and A-FABP are two members of the
lipocalin family, which are produced from mature adipo-
cytes. We hypothesize that adipose tissues secrete these
two adipocytokines via the same mechanism. More im-
portantly, increased RBP4 per se was an independent risk
factor for MetS, even within the lowest A-FABP or CRP
quartile or the highest adiponectin quartile. Therefore, it
is possible that RBP4 may promote MetS risk through a
distinct pathway that does not fully overlap with F-FABP,
CRP or adiponectin.
The obese condition and MetS are accompanied by
low-grade chronic inflammation, which is characterized
by an increased expression of inflammatory cytokines and
infiltration of immune cells in adipocytes [34]. The inflam-
matory response promotes the activation of transcrip-
tional factors and pro-inflammatory cytokines, which can
lead to an unresolved inflammatory response associated
with an inhibition of insulin signaling and a high risk for
cardiovascular events [35]. In the present study, we ob-
served a strong correlation between RBP4 levels and ele-
vated inflammatory markers, including IL-6, MCP-1 and
TNF-α; this correlation has been well documented to play
an important role in the initiation and development of in-
flammatory effects in adipose tissue. Thus, our results
identified proinflammatory markers may be a critical link
between RBP4 and the pathogenesis of MetS.
Accumulating evidence also supports the important
role that oxidative stress plays in MetS-related manifestations
Table 3 OR (and 95% CI) of MetS and its components according to RBP4 quartiles1
RBP4 quartiles
1 2 3 4 P2
Metabolic syndrome (no. cases) 131 171 193 251
Model 13 1.00 1.65 (1.29, 1.99) 2.28 (1.76, 2.89) 3.84 (3.12, 4.58) <0.001
Model 24 1.00 1.61 (1.26, 1.97) 2.15 (1.65, 2.73) 3.46 (2.87, 4.42) <0.001
Model 35 1.00 1.53 (1.21, 1.92) 2.04 (1.58, 2.47) 2.68 (1.95, 3.67) <0.001
Central obesity 183 204 214 331
Model 1 1.00 1.23 (1.02, 1.51) 1.42 (1.08, 1.75) 1.87 (1.48, 2.36) <0.001
Model 2 1.00 1.01 (0.74, 1.32) 0.97 (0.67, 1.28) 0.92 (0.66, 1.35) 0.69
Model 3 1.00 0.94 (0.66, 1.29) 0.87 (0.65, 1.25) 0.81 (0.61, 1.14) 0.23
Hypertriglyceridemia 46 77 112 197
Model 1 1.00 2.13 (1.64, 2.87) 3.45 (2.61, 4.49) 6.75 (5.28, 8.96) <0.001
Model 2 1.00 2.06 (1.52, 2.83) 3.26 (2.47, 4.33) 5.92 (4.47, 8.02) <0.001
Model 3 1.00 1.97 (1.46, 2.68) 3.01 (2.16, 4.08) 5.03 (3.59, 7.45) <0.001
Reduced HDL cholesterol 154 171 177 186
Model 1 1.00 1.24 (1.05, 1.51) 1.38 (1.15, 1.67) 1.76 (1.26, 2.17) <0.001
Model 2 1.00 1.15 (0.97, 1.39) 1.27 (1.04, 1.58) 1.58 (1.17, 1.84) <0.001
Model 3 1.00 1.07 (0.90, 1.26) 1.18 (0.96, 1.51) 1.42 (1.11, 1.68) <0.001
Elevated blood pressure 161 116 117 132
Model 1 1.00 0.93 (0.81, 1.17) 1.02 (0.84, 1.33) 1.10 (0.95, 1.44) 0.32
Model 2 1.00 0.87 (0.76, 1.15) 0.97 (0.81, 1.24) 1.02 (0.84, 1.29) 0.11
Model 3 1.00 0.83 (0.68, 1.10) 0.76 (0.62, 1.02) 0.73 (0.61, 1.16) 0.08
Hyperglycemia 135 167 188 245
Model 1 1.00 1.57 (1.26, 1.95) 1.72 (1.35, 2.14) 3.13 (2.44, 3.93) <0.001
Model 2 1.00 1.50 (1.17, 1.84) 1.67 (1.31, 1.96) 2.74 (2.15, 3.36) <0.001
Model 3 1.00 1.42 (1.06, 1.75) 1.52 (1.23, 1.75) 2.32 (1.85, 2.91) <0.001
1Metabolic syndrome was defined according to the updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian Americans.
2Calculated by using multivariable logistic regression.
3Adjusted for age and sex.
4Adjusted as for model 1 plus BMI (except when modeling associations for central obesity), smoking, drinking, family history of cardiovascular diseases
and diabetes.
5Adjusted as for model 2 plus adiponectin, A-FABP, 8-iso PGF2α, 13-HODE, hsCRP, IL6, MCP1 and TNFα.
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nificantly associated with higher serum 8-iso PGF2-α and
13-HODE, which suggests that a higher RBP4 status may
contribute to oxidative damage. Both 8-iso PGF2-α and
13-HODE are major products of the peroxidation of
unsaturated fatty acids and were shown to be reliable
markers for oxidative stress [37,38]. Thus, the association
of RBP4 with systematic oxidative stress markers in
humans may explain the possible mechanism of a high
RBP4 status on metabolic disorders in humans.
Several limitations of this study need to be addressed.
First, the cross-sectional nature of the study design cannot
be translated into a clear cause–effect inference. Prospective
studies and randomized clinical trials are needed. Second,
as with any observational study, the role of unmeasured or
residual confounding cannot be ruled out; however, themultivariate models did adjust for a wide range of risk fac-
tors that have been implicated in the development of MetS
or its individual components. Finally, we did not distinguish
among full-length and truncated forms of RBP4 that might
have various biological activities with potential varying ef-
fects on metabolic risk factors and MetS. Future studies
with multiple measurements may substantiate our findings.
In conclusion, there was a strong positive association
between plasma RBP4 with the risk of developing MetS
in a middle-aged and elderly Chinese population: sub-
jects with MetS or its components had a higher RBP4
status than those without these conditions. Moreover,
the participants with high plasma RBP4 levels were also
associated with the inflammatory markers and oxidative
stress. Our results suggest a potential link between RBP4
and the incidence of MetS.
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